Amgen lowers earnings estimate after 'solid' quarter

4 August 2021
amgen_big

US biotech Amgen (Nasdaq: AMGN) has seen its quarterly revenues rise by 5% to $6.5 billion in comparison to the second quarter of 2020, a jump attributed to higher unit demand though partially offset by lower net selling prices.

Second-quarter 2021 adjusted earnings, helped by share buybacks, increased 4% from a year ago to $4.38 per share, beating the $4.10 forecast by Wall Street analysts, as calculated by Refinitiv.

On a generally accepted accounting principles (GAAP) basis, Amgen now expects earnings per share in the range of $8.84 to $9.90 for 2021 as a whole, where previously the company had predicted somewhere from $9.11 to $10.71.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology